Acorda Therapeutics Inc (NASDAQ:ACOR) has been given a consensus recommendation of “Hold” by the thirteen brokerages that are currently covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $26.56.

A number of equities research analysts have weighed in on the company. HC Wainwright set a $31.00 target price on Acorda Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 6th. Cantor Fitzgerald set a $32.00 target price on Acorda Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, October 31st. ValuEngine upgraded Acorda Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, August 3rd. JPMorgan Chase & Co. restated a “hold” rating on shares of Acorda Therapeutics in a research report on Wednesday, July 25th. Finally, BidaskClub upgraded Acorda Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 7th.

ACOR opened at $19.13 on Friday. The company has a market capitalization of $940.70 million, a price-to-earnings ratio of 18.39 and a beta of 1.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 4.03 and a quick ratio of 3.95. Acorda Therapeutics has a 1-year low of $15.60 and a 1-year high of $36.35.

Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Wednesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.15. The firm had revenue of $142.80 million during the quarter, compared to the consensus estimate of $82.74 million. Acorda Therapeutics had a positive return on equity of 13.72% and a negative net margin of 24.88%. The firm’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.43 earnings per share. On average, analysts predict that Acorda Therapeutics will post 0.08 EPS for the current fiscal year.

In other Acorda Therapeutics news, major shareholder Scopia Capital Management Lp sold 143,576 shares of the company’s stock in a transaction on Thursday, October 11th. The stock was sold at an average price of $16.98, for a total value of $2,437,920.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 490,832 shares of company stock worth $9,121,364 in the last ninety days. 7.80% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ACOR. Renaissance Technologies LLC increased its holdings in shares of Acorda Therapeutics by 87.3% in the third quarter. Renaissance Technologies LLC now owns 1,275,400 shares of the biopharmaceutical company’s stock valued at $25,062,000 after buying an additional 594,500 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of Acorda Therapeutics by 500.7% in the third quarter. Acadian Asset Management LLC now owns 455,987 shares of the biopharmaceutical company’s stock valued at $8,961,000 after buying an additional 380,072 shares in the last quarter. Baker BROS. Advisors LP bought a new position in shares of Acorda Therapeutics in the second quarter valued at $4,968,000. Prudential Financial Inc. increased its holdings in shares of Acorda Therapeutics by 57.5% in the third quarter. Prudential Financial Inc. now owns 443,131 shares of the biopharmaceutical company’s stock valued at $8,707,000 after buying an additional 161,853 shares in the last quarter. Finally, Matarin Capital Management LLC bought a new position in shares of Acorda Therapeutics in the third quarter valued at $3,082,000.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Further Reading: Put Option

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.